vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and WEYCO GROUP INC (WEYS). Click either name above to swap in a different company.
WEYCO GROUP INC is the larger business by last-quarter revenue ($68.0M vs $60.1M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). WEYCO GROUP INC runs the higher net margin — 9.0% vs -92.6%, a 101.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -0.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 3.1%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Weyco Group is an American footwear company that designs, markets and distributes brand names including Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters and Umi. The company, which focuses on North American wholesale and retail distribution, has been assembled by a series of acquisitions.
RYTM vs WEYS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $60.1M | $68.0M |
| Net Profit | $-55.6M | $6.1M |
| Gross Margin | 88.1% | 44.2% |
| Operating Margin | -87.1% | 11.0% |
| Net Margin | -92.6% | 9.0% |
| Revenue YoY | 83.8% | -0.0% |
| Net Profit YoY | — | 10.4% |
| EPS (diluted) | $-0.83 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $60.1M | $68.0M | ||
| Q4 25 | $57.3M | $76.8M | ||
| Q3 25 | $51.3M | $73.1M | ||
| Q2 25 | $48.5M | $58.2M | ||
| Q1 25 | $32.7M | $68.0M | ||
| Q4 24 | $41.8M | $80.5M | ||
| Q3 24 | $33.3M | $74.3M | ||
| Q2 24 | $29.1M | $63.9M |
| Q1 26 | $-55.6M | $6.1M | ||
| Q4 25 | $-47.5M | $8.7M | ||
| Q3 25 | $-52.9M | $6.6M | ||
| Q2 25 | $-46.6M | $2.3M | ||
| Q1 25 | $-49.5M | $5.5M | ||
| Q4 24 | $-43.3M | $10.0M | ||
| Q3 24 | $-43.6M | $8.1M | ||
| Q2 24 | $-32.3M | $5.6M |
| Q1 26 | 88.1% | 44.2% | ||
| Q4 25 | 91.6% | 44.1% | ||
| Q3 25 | 89.3% | 40.7% | ||
| Q2 25 | 88.6% | 43.3% | ||
| Q1 25 | 88.8% | 44.6% | ||
| Q4 24 | 90.9% | 47.9% | ||
| Q3 24 | 88.5% | 44.3% | ||
| Q2 24 | 89.9% | 43.9% |
| Q1 26 | -87.1% | 11.0% | ||
| Q4 25 | -82.2% | 13.3% | ||
| Q3 25 | -102.6% | 11.0% | ||
| Q2 25 | -93.4% | 6.7% | ||
| Q1 25 | -143.7% | 10.3% | ||
| Q4 24 | -98.6% | 14.3% | ||
| Q3 24 | -132.0% | 13.7% | ||
| Q2 24 | -139.2% | 10.4% |
| Q1 26 | -92.6% | 9.0% | ||
| Q4 25 | -83.0% | 11.3% | ||
| Q3 25 | -103.1% | 9.0% | ||
| Q2 25 | -96.1% | 3.9% | ||
| Q1 25 | -151.4% | 8.1% | ||
| Q4 24 | -103.6% | 12.4% | ||
| Q3 24 | -131.2% | 10.8% | ||
| Q2 24 | -110.9% | 8.8% |
| Q1 26 | $-0.83 | $0.64 | ||
| Q4 25 | $-0.73 | $0.91 | ||
| Q3 25 | $-0.82 | $0.69 | ||
| Q2 25 | $-0.75 | $0.24 | ||
| Q1 25 | $-0.81 | $0.57 | ||
| Q4 24 | $-0.71 | $1.04 | ||
| Q3 24 | $-0.73 | $0.84 | ||
| Q2 24 | $-0.55 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $340.6M | $89.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $122.9M | $243.6M |
| Total Assets | $442.3M | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $340.6M | $89.0M | ||
| Q4 25 | $388.9M | $96.0M | ||
| Q3 25 | $416.1M | $72.9M | ||
| Q2 25 | $291.0M | $77.4M | ||
| Q1 25 | $314.5M | $71.5M | ||
| Q4 24 | $320.6M | $71.0M | ||
| Q3 24 | $298.4M | $75.5M | ||
| Q2 24 | $319.1M | $78.4M |
| Q1 26 | $122.9M | $243.6M | ||
| Q4 25 | $139.1M | $239.6M | ||
| Q3 25 | $148.8M | $251.3M | ||
| Q2 25 | $-11.9M | $248.1M | ||
| Q1 25 | $18.9M | $248.6M | ||
| Q4 24 | $21.7M | $245.6M | ||
| Q3 24 | $11.2M | $258.1M | ||
| Q2 24 | $39.3M | $251.2M |
| Q1 26 | $442.3M | $296.3M | ||
| Q4 25 | $480.2M | $319.7M | ||
| Q3 25 | $506.9M | $304.0M | ||
| Q2 25 | $372.7M | $300.9M | ||
| Q1 25 | $386.7M | $299.3M | ||
| Q4 24 | $392.3M | $324.1M | ||
| Q3 24 | $363.6M | $314.7M | ||
| Q2 24 | $381.8M | $303.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $17.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 2.85× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $17.4M | ||
| Q4 25 | $-25.4M | $24.0M | ||
| Q3 25 | $-26.6M | $-1.1M | ||
| Q2 25 | $-23.3M | $10.2M | ||
| Q1 25 | $-40.4M | $4.1M | ||
| Q4 24 | $-18.8M | $20.4M | ||
| Q3 24 | $-25.2M | $-374.0K | ||
| Q2 24 | $-29.1M | $3.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $23.1M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $10.0M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | — | $-930.0K | ||
| Q2 24 | — | $3.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.1% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | 17.1% | ||
| Q1 25 | — | 5.5% | ||
| Q4 24 | — | 24.8% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | — | 4.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.3% |
| Q1 26 | — | 2.85× | ||
| Q4 25 | — | 2.76× | ||
| Q3 25 | — | -0.17× | ||
| Q2 25 | — | 4.53× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 2.04× | ||
| Q3 24 | — | -0.05× | ||
| Q2 24 | — | 0.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
